Targeted Therapy for Ovarian Cancer: 35 Real Stories

35 stories match ovarian cancer and targeted therapy. 33 of them mention chemotherapy.

A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
Jackie, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Jackie's Survivor Story

Patient Info: Jackie Page, Female, 50s | Stage III

In remission with no sign of recurrent disease at the September 2020 publication, while continuing treatment on the clinical trial.

Dana-Farber
OutcomeCancer-Free / NED
Patty, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III BRCA1 Ovarian Cancer: Patty's Patient Story

Patient Info: Patty Klein, Female | Stage III

Biomarkers: BRCA1 mutation

Patty was able to continue the olaparib plus BKM120 clinical trial as long as her tumor remained controlled. She later died.

AACR
OutcomeIn Memory
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Stable Brain Metastases During Niraparib Maintenance for Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CA-125 4019 kU/L; pathogenic germline BRCA1 mutation

Metastatic Site: brain

After 17 months of niraparib, her brain metastases remained stable. She had a performance status of 0 and reported a full, normal quality of life.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Cancer Relapse Causing Fluid Around the Heart

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: PAX8 positive; CK7 positive; WT1 positive; p53 positive; ER positive; PR negative; isolated PMS2 loss; MSH2 retained; MSH6 retained; MLH1 retained; two BRCA1 variants of uncertain significance

Metastatic Site: omentum|pericardium

She was alive after completing chemotherapy for the pericardial relapse and was receiving olaparib maintenance. The fluid around the heart did not recur immediately after the surgical window.

PubMed Central
OutcomeCare Ongoing
AO
Ovarian Cancer

Advanced Ovarian Cancer Presenting With Dermatomyositis

Patient Info: Anonymized, Female, 50s

Biomarkers: CA-125 3169 at diagnosis; later CA-125 rise with progression

After a partial response to second-line chemotherapy, nodal disease progressed again 5 months later and liposomal doxorubicin was planned.

PubMed Central
OutcomeSetback / Progression
OC
Ovarian Cancer

Ovarian Cancer With Pleural Spread and Recurrent Dermatomyositis

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Metastatic Site: pleura

She had symptomatic improvement after 2 cycles of carboplatin and liposomal doxorubicin for recurrent disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Ovarian CancerOvarian Cancer

Metastatic Low-Grade Serous Ovarian Cancer Causing Severe Pulmonary Hypertension

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: pleura, pulmonary arteries

She died on hospital day 29 after rapidly progressive pulmonary hypertension. Autopsy attributed the pulmonary hypertension to metastatic ovarian serous carcinoma with pulmonary arterial tumor emboli.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury

Patient Info: Anonymized, female, 70+ | Stage III

After further intra-abdominal cancer progression and severe kidney injury, she developed seizures, encephalopathy, and limb ischemia and died 1 week after hospitalization in May 2011.

PubMed Central
OutcomeIn Memory